Saturday Sessions

Session 1

INT1 management in MF

Session 2

Future directions in CML

Translating CML TFR data into clinical practice

MRD and its place in AML

Session 3

Evolving treatment algorithm in AML

Transplantation in AML

Session 4

Recent updates in management of lower risk MDS

Management of relapsed/refractory diffuse large B cell lymphoma (DLBCL)

Sunday Sessions

Session 5

CAR T-cell therapy for pALL: identifying appropriate patients and maximising outcomes

CAR T-cell therapy for Lymphoma: Patient identification, management and predictors of response and relapse

Setting up a site to deliver CAR T therapy: Australian experience

Session 6

Management of CAR T related adverse events

Cancer Therapy-induced Cardiotoxicity

Scroll to top